GST Boehringer Ingelheim
  • image

    “Look at the stars
    and not at your feet”
    S. Hawking

    Global Stem cell Technology joins Boehringer Ingelheim 

    After two years of a successful partnership with Boehringer Ingelheim that brought the first-ever registered stem cell-based veterinary medicine to the European market, we decided to join the big Boehringer Ingelheim family.

    Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

    Boehringer Ingelheim is also a global leader in animal health striving to continue to set new standards of care for animals and develop breakthrough solutions that change lives. We believe that by being part of Boehringer Ingelheim, our expertise in the field of state-of-the-art stem cell solutions will contribute even more significantly to jointly developed innovation in the equine and pet markets. Stem cell treatments can help combat the underlying root cause of a disease beyond symptom, which represents an enormous potential for animals and companies such as ours and Boehringer Ingelheim as we both are driven by innovation.

    We look forward to joining forces with such a strong global player and on behalf of all of us at Global Stem cell Technology, we want to reassure you of our long-standing commitment to support you with innovative solutions and our continuous passion and drive to address unmet needs.

    For more information on this transaction, please contact


    6th of February 2020:
    GST represented the industry at the Conference on Annex 2 of the new veterinary medicines Regulation 2019/6 in Munich.
    Great organization by Klifovet!

    June 21 2018

    Current Veterinary Practices (CCVP)

    GST organizes the Conference on Current Veterinary Practices (CCVP) together with two other pharmaceutical companies Eickemeyer and Orthopaedics.

    The CCVP aims at bringing equine veterinarians together to discuss the latest insights in veterinary surgery, medical imaging, drug treatments and horse care. It is  an interactive and practical forum in which equine veterinarians can debate emerging new clinical insights as well as practical experiences with participants and presenters in different areas of expertise.

    We already organized 6 conferences in Belgium and the Nederlands and the 7th CCVP will be held on October 5th 2018.

    For more information on the CCVP, to download the proceedings of previous conferences or to register for the next conference please visit


    Read our press and magazine articles:

    11 september 2018

    Wereldprimeur voor biotechpionier uit Evergem

    Op 21 juni 2018 gaf het Europese Geneesmiddelenagentschap groen licht voor Arti-Cell Forte, het eerste diergeneeskundig product op basis van stamcellen ter wereld. Het werd ontwikkeld door het Evergemse biotechbedrijf GST, onderdeel van Anacura. " We hebben nog zes medicijnen in de pijplijn, zowel voor paarden als voor honden", vertelt oprichter Jan Spaas.

    22 juni 2018

    First stem cell-based veterinary medicine recommended for marketing authorisation

    Arti-Cell Forte is indicated in horses with mild to moderate lameness due to joint inflammation

    21 juni 2018

    Evergems veterinair biotech bedrijf, koploper in Europa!

    Volgens een recente marktstudie bij meer dan 10.500 paardeneigenaars blijkt dat gewrichtsaandoeningen hun grootste bezorgdheid is. Dit is een terechte bezorgdheid aangezien 25% van de paarden hiermee te kampen krijgt op een bepaald punt in hun leven (=1,4 miljoen in de EU).

    21 juni 2018

    CrossRoads2 project Artitera

    Osteoarthritis is a common, painful and progressive disease, which severely compromises the quality of life of both horses and humans.

    16 mei 2018

    Gentse paardengenezer haalt 5 miljoen euro op

    Een Gentse ex-topruiter heeft een stamceltherapie ontwikkeld om artrose bij paarden te genezen.